Skip to content

Cardiac Effects From Radiation Therapy by MRI

Identification of Early Cardiac Injury From Radiation Therapy Using Cardiac Magnetic Resonance Imaging

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04486573
Enrollment
6
Registered
2020-07-24
Start date
2020-07-15
Completion date
2023-09-14
Last updated
2024-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Cardiotoxicity, Radiation Treatment

Brief summary

The investigators will identify 10 patients in the department of radiation oncology who will receive standard of-care radiation therapy, and the treating radiation oncologist anticipates a mean left ventricular dose of at least 5 Gy. Patients will be evaluated by CMRI before and within one week of the completion of RT. We will compare the pre- and post-RT CMRI scans to identify changes related to radiation exposure. Our primary endpoint will be changes in myocardial strain. Secondary endpoints will include other CMRI parameters.

Detailed description

Cardiac toxicity is a significant cause of morbidity and mortality in cancer survivors after radiation therapy (RT) to the chest. Typically, cardiotoxicity is identified years after radiation exposure. Emerging clinical data show that subclinical injury can be identified immediately after treatment. Early identification of subclinical injury may enable intervention to reduce the risk of progression to clinically significant toxicity. The investigators hypothesize that cardiac magnetic resonance imaging (CMRI) will detect early cardiac injury after RT and that imaging changes will be associated regionally with cardiac radiation dose.

Interventions

DIAGNOSTIC_TESTCardiac Magnetic Resonance Imaging

A cardiac MRI is a painless imaging test that uses radiowaves, magnets, and a computer to create detailed pictures of the heart.

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. Provision to sign and date the consent form. 2. Stated willingness to comply with all study procedures and be available for the duration of the study. 3. 18 - 100 years of age 4. KPS ≥ 70 or ECOG ≥ 1 5. Will receive RT using computed tomography (CT)-based treatment planning that will involve delivery of dose to the heart 6. Estimated by the treating radiation oncologist at the time of simulation to have a mean left ventricular dose of at least 5 Gy

Exclusion criteria

1. Previous history of RT to the thorax or breast 2. Implanted device that is non-MRI compatible or any implanted device in chest 3. Known gadolinium contrast allergy or other contraindication to CMRI scan. Patients needing sedation or medication for claustrophobia or anxiety will not be excluded from participating. 4. Found to be pregnant or breast-feeding 5. Known history of atrial fibrillation or frequent ventricular or atrial premature beats 6. Known history of chronic kidney disease (such as, but not limited, to a glomerular filtration rate \< 60mL/min) 7. History of coronary artery disease or myocardial disease 8. History of hypertension, requiring \>1 antihypertensive agent to maintain blood pressure \<140/90 9. Known history of valvular stenosis or regurgitation of \> moderate severity 10. Known history of heart failure (defined as baseline New York Heart Association Class III or IV (see Appendix A) 11. Systolic blood pressure \< 90mmGy 12. Pulse \< 50/minute 13. Known history of pulmonary hypertension or elevated right ventricular systolic pressures. 14. Suspicion or diagnosis of amyloidosis 15. Suspicion or diagnosis of hemochromatosis

Design outcomes

Primary

MeasureTime frameDescription
Change in myocardial strain2 yearsAssess for a change in myocardial strain, as measured by CMRI scans performed before and after RT

Secondary

MeasureTime frameDescription
Extracellular volume fraction2 yearsMeasured by scans performed before and after RT
T2 values2 yearsMeasured by scans performed before and after RT
Late gadolinium enhancement2 yearsMeasured by scans performed before and after RT
Left ventricular ejection fraction2 yearsMeasured by scans performed before and after RT
T1 pre- and post-contrast values2 yearsMeasured by scans performed before and after RT
End systolic volume2 yearsMeasured by scans performed before and after RT
Left atrial volume2 yearsMeasured by scans performed before and after RT
Wall thickness2 yearsMeasured by scans performed before and after RT
Left ventricular mass index2 yearsMeasured by scans performed before and after RT
End diastolic volume2 yearsMeasured by scans performed before and after RT

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026